000132432 001__ 132432
000132432 005__ 20240229105015.0
000132432 0247_ $$2doi$$a10.1007/s00259-017-3870-6
000132432 0247_ $$2pmid$$apmid:29124281
000132432 0247_ $$2ISSN$$a0340-6997
000132432 0247_ $$2ISSN$$a1432-105X
000132432 0247_ $$2ISSN$$a1619-7070
000132432 0247_ $$2ISSN$$a1619-7089
000132432 0247_ $$2altmetric$$aaltmetric:28768580
000132432 037__ $$aDKFZ-2018-00120
000132432 041__ $$aeng
000132432 082__ $$a610
000132432 1001_ $$00000-0002-4071-5217$$aAnwar, Hoda$$b0$$eFirst author
000132432 245__ $$aAbsolute number of new lesions on18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.
000132432 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2018
000132432 3367_ $$2DRIVER$$aarticle
000132432 3367_ $$2DataCite$$aOutput Types/Journal article
000132432 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521456231_12159
000132432 3367_ $$2BibTeX$$aARTICLE
000132432 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132432 3367_ $$00$$2EndNote$$aJournal Article
000132432 520__ $$aEvaluation of response to immunotherapy is a matter of debate. The aim of the present study was to evaluate the response of metastatic melanoma to treatment with ipilimumab by means of18F-FDG PET/CT, using the patients' clinical response as reference.The final cohort included in the analyses consisted of 41 patients with metastatic melanoma who underwent18F-FDG PET/CT before and after administration of ipilimumab. After determination of the best clinical response, the PET/CT scans were reviewed and a separate independent analysis was performed, based on the number and functional size of newly emerged18F-FDG-avid lesions, as well as on the SUV changes after therapy.The median observation time of the patients after therapy was 21.4 months (range 6.3-41.9 months). Based on their clinical response, patients were dichotomized into those with clinical benefit (CB) and those without CB (No-CB). The CB group (31 patients) included those with stable disease, partial remission and complete remission, and the No-CB group (10 patients) included those with progressive disease. The application of a threshold of four newly emerged18F-FDG-avid lesions on the posttherapy PET/CT scan led to a sensitivity (correctly predicting CB) of 84% and a specificity (correctly predicting No-CB) of 100%. This cut-off was lower for lesions with larger functional diameters (three new lesions larger than 1.0 cm and two new lesions larger than 1.5 cm). SUV changes after therapy did not correlate with clinical response. Based on these findings, we developed criteria for predicting clinical response to immunotherapy by means of18F-FDG PET/CT (PET Response Evaluation Criteria for Immunotherapy, PERCIMT).Our results show that a cut-off of four newly emerged18F-FDG-avid lesions on posttherapy PET/CT gives a reliable indication of treatment failure in patients under ipilimumab treatment. Moreover, the functional size of the new lesions plays an important role in predicting the clinical response. Validation of these results in larger cohorts of patients is warranted.
000132432 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000132432 588__ $$aDataset connected to CrossRef, PubMed,
000132432 7001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b1$$udkfz
000132432 7001_ $$aWinkler, Julia$$b2
000132432 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b3$$udkfz
000132432 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b4$$udkfz
000132432 7001_ $$aHassel, Jessica C$$b5
000132432 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b6$$eLast author$$udkfz
000132432 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-017-3870-6$$gVol. 45, no. 3, p. 376 - 383$$n3$$p376 - 383$$tEuropean journal of nuclear medicine and molecular imaging$$v45$$x1619-7089$$y2018
000132432 909CO $$ooai:inrepo02.dkfz.de:132432$$pVDB
000132432 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-4071-5217$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132432 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132432 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132432 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132432 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000132432 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000132432 9141_ $$y2018
000132432 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132432 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132432 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132432 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000132432 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000132432 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000132432 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132432 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132432 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132432 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132432 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132432 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132432 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000132432 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x0
000132432 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000132432 980__ $$ajournal
000132432 980__ $$aVDB
000132432 980__ $$aI:(DE-He78)E060-20160331
000132432 980__ $$aI:(DE-He78)C060-20160331
000132432 980__ $$aUNRESTRICTED